There are currently 186 clinical trials in Coral Gables, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including UM Sylvester Comprehensive Cancer Center at Coral Gables, University of Miami, Clinical Research of South Florida and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892
Recruiting
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/02/2024
Locations: GSK Investigational Site, Coral Gables, Florida
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA
NCT06437171
Recruiting
This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/06/2024
Locations: AAADRS Clinical Research Center, Coral Gables, Florida
Conditions: Food Allergy
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
The Less is More Study
NCT05153811
Recruiting
In this project, the investigators will implement innovations to extend use of Contingency Management (CM) to facilitate alcohol use reduction among people living with HIV (PLWH). The investigators' approach to extending CM will use mobile health (mHealth) tools including a smartphone breathalyzer device with accompanying app and a wrist worn alcohol biosensor. Participants will be engaged in mobile facilitated CM for 30-60 days with follow-up out to 6 months.
Gender:
ALL
Ages:
Between 35 years and 70 years
Trial Updated:
06/20/2024
Locations: University of Miami, Coral Gables, Florida
Conditions: Alcohol Use
Register for Updates
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
NCT06108024
Recruiting
The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12-weeks post final application for a total of approximately 16-weeks of required participation in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Driven Research LLC, Coral Gables, Florida
Conditions: Seborrheic Keratosis
Register for Updates
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
NCT05090267
Recruiting
This project uses a hybrid trial design to evaluate two biomedical interventions targeting the gut-brain axis. One intervention is portable Transcutaneous Vagus Nerve Stimulator, tVNS, that is hypothesized to stimulate the autonomic nervous system, resulting in decreased inflammation and improved cognition. The second intervention is a probiotic supplement intended to replace gut bacteria that are associated with dysbiosis in persons with HIV and alcohol consumption.
Gender:
ALL
Ages:
Between 35 years and 70 years
Trial Updated:
05/08/2024
Locations: University of Miami, Coral Gables, Florida
Conditions: Cognition, Gut Microbiome
Register for Updates
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589
Recruiting
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: University of Miami, Coral Gables, Florida
Conditions: Neurotrophic Keratopathy
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Hi Tech and Global Research, Coral Gables, Florida
Conditions: NASH, Cirrhosis, Liver
Register for Updates
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of Miami, Coral Gables, Florida
Conditions: COVID-19
Register for Updates
Alpha-1 Research Registry
NCT04157049
Recruiting
The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The Registry was established to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1.
Gender:
ALL
Ages:
All
Trial Updated:
01/29/2024
Locations: Alpha-1 Foundation, Coral Gables, Florida
Conditions: Alpha 1-Antitrypsin Deficiency
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Hi Tech and Global Research, LLC, Coral Gables, Florida
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates